Soft drugs for future treatment of chronic obstructive pulmonary disease (COPD)
1Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander University, Erlangen, Germany. szelenyi@pharmakologie.uni-erlangen.de
Abstract:
COPD is a major cause of chronic morbidity and mortality worldwide. Current treatment is aimed at symptomatic relief. In contrast to bronchial asthma, glucocorticoid treatment strategies have proved disappointing. Consequently, there is a need to develop more effective therapeutic strategies to replace present treatment. Advances in understanding the pathogenesis of COPD have the potential for identifying new therapeutic targets. Additionally, forgotten old compounds might undergo a revival by means of novel pharmaceutical technology.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-I: Introduction
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...


